NuCana PLC (NCNA)
Stock Price:
$5.23 USD
-0.16 (-2.97%)
Updated Jul 6, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
167.25M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-24.42M |
| Shares Out |
32.48M |
| EPS (ttm) |
-0.63 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 6, 2020 |
| Last Price |
$5.23 |
| Previous Close |
$5.39 |
| Change ($) |
-0.16 |
| Change (%) |
-2.97% |
| Day's Open |
5.42 |
| Day's Range |
5.23 - 5.56 |
| Day's Volume |
0 |
| 52-Week Range |
3.81 - 10.94 |
More Stats
| Market Cap |
167.25M |
| Enterprise Value |
110.11M |
| Earnings Date (est) |
Aug 19, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
32.48M |
| Float |
16.31M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.63 |
| FCF / Share |
-0.95 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.49M |
| Short Ratio |
23.88 |
| Short % of Float |
n/a |
| Beta |
1.11 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.52 |
| Revenue |
n/a |
| Operating Income |
-33.58M |
| Net Income |
-24.42M |
| Free Cash Flow |
-30.90M |
| Net Cash |
57.14M |
| Net Cash / Share |
1.79 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-23.06% |
| ROE |
-29.21% |
| ROIC |
-300.00% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$17.29*
(230.60% upside)
Low
13.2
Current: 5.23
High
21.4
Target: 17.29
*Average 12-month USD price target from 5 stock analysts.
Financial Performance
Financial numbers in millions GBP.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -25.68 | -22.03 | -24.04 | -9.05 | -6.91 |
| Net Income | -21.41 | -13.84 | -23.09 | -6.05 | -5.33 |
| Shares Outstanding | 32.23 | 31.81 | 31.81 | 31.81 | - |
| Earnings Per Share | -0.66 | -0.43 | -0.89 | -0.25 | -0.22 |
| Operating Cash Flow | -23.85 | -16.45 | -8.99 | -10.37 | -5.50 |
| Capital Expenditures | -1.26 | -1.62 | -1.10 | -0.55 | -0.40 |
| Free Cash Flow | -25.11 | -18.07 | -10.09 | -10.92 | -5.89 |
| Cash & Equivalents | 51.96 | 76.97 | 86.70 | 19.99 | 29.19 |
| Total Debt | 0.81 | - | - | - | - |
| Net Cash / Debt | 51.16 | 76.97 | 86.70 | 19.99 | 29.19 |
| Assets | 70.27 | 87.19 | 96.36 | 27.21 | 31.69 |
| Liabilities | 6.75 | 5.59 | 2.94 | 1.97 | 1.73 |
| Book Value | 63.52 | 81.59 | 93.42 | 25.24 | 29.96 |
Numbers in millions GBP, except per-share numbers.
Company Details
| Full Name |
NuCana PLC |
| Country |
United Kingdom |
| Employees |
29 |
| CEO |
Hugh Stephen Griffith |
Stock Information
| Ticker Symbol |
NCNA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NCNA |
| IPO Date |
September 28, 2017 |
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase Ib and Phase III clinical trials for the treatment of patients with biliary tract cancer; a Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trial for the treatment of patients with biliary cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.